NCT05800873

Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001

A Phase 1b/2 Study To Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001 In Participants With Selected Proteinuric Glomerular Diseases

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Everest Medicines (China) Co.,Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

EVER001 is a highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases, which is being developed to treat proteinuric glomerular diseases. The overall aim of the study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of EVER001 in subjects with selected proteinuric glomerular diseases. The first targeted disease is primary membranous nephropathy.

Conditions

• Primary Membranous Nephropathy

Interventions

Type	Name	Description
DRUG	EVER001	A highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases.
DRUG	EVER001	A highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases.

Timeline

• Start date: 2023-05-15
• Primary completion: 2026-09-15
• Completion: 2026-09-15
• First posted: 2023-04-06
• Last updated: 2025-05-31

Locations

19 sites across 1 country: China